Pfizer's two cancer candidates accepted for EMA review
This article was originally published in Scrip
Executive Summary
The European Medicine’s Agency has accepted for regulatory review, two of Pfizer’s cancer therapies. The first is an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, crizotinib, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC). The second product is bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) in the chronic phase.